ArticleEClinicalMedicine2023
Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis.
Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.Annals of hematology · 2024Pooled it
- A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.British journal of haematology · 2026Trial
- β2-adrenergic receptor agonist regulates macrophage polarization via HMGB1 in immune thrombocytopenia.Science China. Life sciences · 2026Article
- Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia.Blood advances · 2026Article
- Emerging targeted therapies for primary immune thrombocytopenia: novel agents, combination strategies, and future directions.Frontiers in pharmacology · 2026Review
- Optimization of thrombopoietin mimetic peptide fusion proteins with albumin-binding domain for enhanced bioactivity and extended half-life.Scientific reports · 2025Article
- Integrated sampling and in situ SERS detection of diquat and paraquat using silver nanostars-modified PTFE substrates.Mikrochimica acta · 2025Article
- Treatment effectiveness of hydroxychloroquine in patients with primary Sjögren's syndrome: a real-world Study.Clinical rheumatology · 2025Article
- Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study.European journal of medical research · 2025Article
- The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches.Frontiers in immunology · 2025Review
- Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy.Hematology. American Society of Hematology. Education Program · 2024Review
- The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune thrombocytopenia is an autoimmune disease characterised by decreased platelet count. In recent years, novel therapeutic regimens have been investigated in randomised controlled trials (RCTs). We aimed to compare the efficacy and safety of different treatments in newly diagnosed adult primary immune thrombocytopenia. Methods: We did a systematic review and network meta-analysis of RCTs involving treatments for newly diagnosed primary immune thrombocytopenia. PubMed, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched up to April 31, 2022. The primary outcomes were 6-month sustained response and early response. Secondary outcome was grade 3 or higher adverse events. This study is registered with PROSPERO (CRD42022296179). Findings: Eighteen RCTs (n = 1944) were included in this study. Pairwise meta-analysis showed that the percentage of patients achieving early response was higher in the dexamethasone-containing doublet group than in the dexamethasone group (79.7% Interpretation: Our findings suggested that compared with monotherapy dexamethasone or prednis(ol)one, the combined regimens had better early and sustained responses. rhTPO plus dexamethasone ranked top in early response, while rituximab plus corticosteroids obtained the best sustained response, but with more adverse events. Adding oseltamivir, all-trans retinoic acid or tacrolimus to dexamethasone reached equally encouraging sustained response, without compromising safety profile. Although this network meta-analysis compared all the therapeutic regimens up to date, more head-to-head RCTs with larger sample size are warranted to make direct comparison among these strategies. Funding: National Natural Science Foundation of China, Major Research Plan of National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation and Young Taishan Scholar Foundation of Shandong Province.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.